Premium
Truth in clinical research trials involving pharmaceutical sponsorship
Author(s) -
Commons Chris A
Publication year - 2001
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2001.tb143478.x
Subject(s) - clinical trial , informed consent , medicine , adverse effect , alternative medicine , drug , new drug application , drug reaction , family medicine , business , pharmacology , pathology
Large clinical trials are expensive to mount. Funding comes mainly from pharmaceutical companies seeking information on drug efficacy and adverse events. Patients should be informed of the financial and publication agreements reached between those conducting the trials. This is unlikely to have a significant effect on trial participation and will provide patients with information relevant to informed consent. A small proportion of monies raised from drug trials could be set aside to fund both a trial register site and further studies on adverse drug reactions.